Form 8-K - Current report:
SEC Accession No. 0001628280-25-032627
Filing Date
2025-06-23
Accepted
2025-06-23 16:34:39
Documents
15
Period of Report
2025-06-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20250623.htm   iXBRL 8-K 54035
2 EX-5.1 a51opinionq22025.htm EX-5.1 14361
3 EX-10.1 exq22025lpc.htm EX-10.1 328311
4 EX-10.2 ex10-1q22025rr.htm EX-10.2 130842
  Complete submission text file 0001628280-25-032627.txt   736545

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20250623.xsd EX-101.SCH 1785
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20250623_lab.xml EX-101.LAB 23451
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20250623_pre.xml EX-101.PRE 13583
17 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20250623_htm.xml XML 2824
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 251065351
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)